Healthcare | May 08, 2026
Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
Report highlights growing confidence in digitalisation and AI, even as healthcare leaders remain concerned about workforce gaps, cybersecurity, and data readiness
Leadership transition strengthens Redcliffe Labs’ focus on scaling technology-led diagnostics, operational excellence, and preventive healthcare access
Subscribe To Our Newsletter & Stay Updated
